Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Heart Journal Pubmed

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

Download PDF

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James, Stefan; Akerblom, Axel; Cannon, Christopher P; Emanuelsson, Håkan; Husted, Steen; Katus, Hugo; Skene, Allan; Steg, Philippe Gabriel; Storey, Robert F; Harrington, Robert; Becker, Richard; Wallentin, Lars
American Heart Journal , Volume 157 (4): 7 – Apr 21, 2009

Loading next page...
 
/lp/pubmed/comparison-of-ticagrelor-the-first-reversible-oral-p2y-12-receptor-D3Q8N0YS7V

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0002-8703
DOI
10.1016/j.ahj.2009.01.003
pmid
19332184

Abstract

Journal

American Heart Journal – Pubmed

Published: Apr 21, 2009

There are no references for this article.